CN1287835C - 一种治疗冠心病、心绞痛的药物组合物及其制备方法 - Google Patents
一种治疗冠心病、心绞痛的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1287835C CN1287835C CN 200410057369 CN200410057369A CN1287835C CN 1287835 C CN1287835 C CN 1287835C CN 200410057369 CN200410057369 CN 200410057369 CN 200410057369 A CN200410057369 A CN 200410057369A CN 1287835 C CN1287835 C CN 1287835C
- Authority
- CN
- China
- Prior art keywords
- radix
- weight portion
- hours
- add
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 16
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 230000008569 process Effects 0.000 title description 2
- 241000219780 Pueraria Species 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 456
- 239000007788 liquid Substances 0.000 claims description 116
- 241000756943 Codonopsis Species 0.000 claims description 74
- 239000000706 filtrate Substances 0.000 claims description 69
- 238000010992 reflux Methods 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 239000009636 Huang Qi Substances 0.000 claims description 42
- 241000195474 Sargassum Species 0.000 claims description 41
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 41
- 238000004321 preservation Methods 0.000 claims description 38
- 238000004064 recycling Methods 0.000 claims description 35
- 241000533849 Gleditsia Species 0.000 claims description 34
- 241001523579 Ostrea Species 0.000 claims description 34
- 230000006837 decompression Effects 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 tincture Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 1
- 241001474374 Blennius Species 0.000 abstract 1
- 241000950640 Calcarius Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241000931143 Gleditsia sinensis Species 0.000 abstract 1
- 241001448421 Ophiopogon jaburan Species 0.000 abstract 1
- 241000237502 Ostreidae Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 33
- 235000019198 oils Nutrition 0.000 description 33
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
- 238000001694 spray drying Methods 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 238000007908 dry granulation Methods 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- 235000019359 magnesium stearate Nutrition 0.000 description 16
- 230000003203 everyday effect Effects 0.000 description 14
- 238000012856 packing Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- 230000002107 myocardial effect Effects 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 7
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010009 beating Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000008899 fufang danshen Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012109 statistical procedure Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010038669 Respiratory arrest Diseases 0.000 description 2
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000288029 Coturnix Species 0.000 description 1
- 241000334119 Coturnix japonica Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000594163 Japonia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | 例数(只) | 剂量(g/kg ip) | 存活时间(X±SD分) | 提高存活时间(%) |
生理盐水对照组丹参注射液组丹能注射液组本发明药液组本发明药液组 | 1313131313 | 15301530 | 20±334±9**43±11**32±8**44±10** | 7011560120 |
组别 | 标本数 | 心肌细胞停播时间(min) |
本发明药液组生理盐水对照组复方丹参对照组 | 101010 | 119.2±22.97**96.4±14.54108.3±18.25 |
组别 | 剂量(g/100g/d) | 灌胃给药天数 | Ch值(n=10) | TG值(n=10) |
(mg/dl) | (mg/dl) | |||
脉安颗粒维生素E本发明药液(高)本发明药液(低)高脂对照正常对照 | 130.02184.02.0等容量水等容量水 | 141414141414 | 324.76±89.66**240.33±30.74**469.48±116.75**560.52±118.52636.18±124.15109.38±16.45** | 47.27±14.62**92.82±29.28**95.63±29.09**166.73±52.12190.57±61.8249.82±5.23** |
组别 | 剂量(g/100g/d) | 灌胃给药天数 | HDL-C值(n=10)(mg/dl) |
脉安颗粒维生素E本发明药液(高)本发明药液(低)高脂对照正常对照 | 1.30.02184.02.0等容量水等容量水 | 141414141414 | 53.81±11.3373.25±5.0180.13±28.6552.35±11.4547.82±11.5451.45±10.94 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410057369 CN1287835C (zh) | 2004-08-30 | 2004-08-30 | 一种治疗冠心病、心绞痛的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410057369 CN1287835C (zh) | 2004-08-30 | 2004-08-30 | 一种治疗冠心病、心绞痛的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1628837A CN1628837A (zh) | 2005-06-22 |
CN1287835C true CN1287835C (zh) | 2006-12-06 |
Family
ID=34846202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410057369 Expired - Lifetime CN1287835C (zh) | 2004-08-30 | 2004-08-30 | 一种治疗冠心病、心绞痛的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1287835C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108969561A (zh) * | 2018-08-29 | 2018-12-11 | 李杨林 | 一种用于治疗机体供血供氧不足的中药及其制备方法 |
CN114246903B (zh) * | 2020-09-23 | 2023-12-05 | 鲁南厚普制药有限公司 | 心通制剂在制备治疗慢性支气管炎药物中的应用及其制备方法 |
CN113876885A (zh) * | 2021-11-10 | 2022-01-04 | 山东新时代药业有限公司 | 一种心通制剂的制备方法 |
-
2004
- 2004-08-30 CN CN 200410057369 patent/CN1287835C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1628837A (zh) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1686352A (zh) | 一种治疗高脂血症的药物及其生产方法 | |
CN1245198C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN101062084A (zh) | 一种抗肝炎的药物组合物 | |
CN1901926A (zh) | 含有葫芦科植物提取物或者从其中分离的具有抗脂肪形成和抗肥胖症活性的纯化提取物的组合物 | |
CN1559519A (zh) | 一种夏枯草提取物及其制备方法与用途 | |
CN1923241A (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN1287835C (zh) | 一种治疗冠心病、心绞痛的药物组合物及其制备方法 | |
CN100341492C (zh) | 一种参芪降糖软胶囊及其制备检测方法 | |
CN1651041A (zh) | 姬松茸水溶性小分子提取物及其制备工艺和用途 | |
CN1947747A (zh) | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 | |
CN1931233A (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN101049293A (zh) | 乙酰半胱氨酸或其药用盐和细辛脑的药物组合物 | |
CN101053566A (zh) | 乙酰半胱氨酸或其盐和抗感染药物的组合物 | |
CN1650996A (zh) | 一种药物组合物及其制备方法和应用 | |
CN101040886A (zh) | 灯盏花和丹参酮ⅱa磺酸钠的药用组合物 | |
CN101062027A (zh) | 牛磺酸和治疗心脑血管疾病的药物的组合物 | |
CN1709238A (zh) | 一种具有保肝作用的静脉注射用粉针及其制备与质量控制方法 | |
CN1631895A (zh) | 苦杏仁苷的制备方法和苦杏仁苷在制备促进心脑胰及伤口血液循环的苦杏仁苷制剂中的应用 | |
CN1954870A (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1554407A (zh) | 一种清肺化痰止咳平喘的药物及其制备方法 | |
CN1586604A (zh) | 一种莪术注射制剂及其制备方法 | |
CN1557395A (zh) | 一种治疗类风湿性关节炎的清络通痹制剂及其制备方法 | |
CN1579485A (zh) | 治疗肠功能紊乱的中药组合物及其制备方法 | |
CN100341490C (zh) | 一种参芪降糖分散片及其制备检测方法 | |
CN1709439A (zh) | 一种参芪降糖滴丸及其制备检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LUNAN PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: LUNAN PHARMACY CO. LTD. Effective date: 20050812 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050812 Address after: 276005 No. 209 Hongqi Road, Shandong, Linyi Applicant after: LUNAN PHARMACEUTICAL Group Corp. Address before: No. 107, Linxi, Linyi, Shandong Applicant before: Lunan Pharmaceutical Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000516 Denomination of invention: Pharmaceutical composition for treating coronary heart disease and angina pectoris and its preparing process Granted publication date: 20061206 License type: Exclusive License Open date: 20050622 Record date: 20100909 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000516 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050622 Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2013370000262 Denomination of invention: Pharmaceutical composition for treating coronary heart disease and angina pectoris and its preparing process Granted publication date: 20061206 License type: Exclusive License Record date: 20131210 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20061206 |